• Explore /
  • Poster
  • / Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).

Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101).

Abstract Poster

Authors

Toni Choueiri

Toni K. Choueiri

Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA

Toni K. Choueiri , Brian I. Rini , James M. G. Larkin , Georg A. Bjarnason , Gwenaelle Gravis , Howard Gurney , Jae-Lyun Lee , Daniel Keizman , John B. A. G. Haanen , Yoshihiko Tomita , Hirotsugu Uemura , Laurence Albiges , Manuela Schmidinger , Michael B. Atkins , Mariangela Mariani , Michael Shnaidman , Alessandra di Pietro , Robert J. Motzer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02684006

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS4594)

DOI

10.1200/JCO.2017.35.15_suppl.TPS4594

Abstract #

TPS4594

Poster Bd #

270a

Abstract Disclosures

Similar Posters

First Author: Masatoshi Kudo

First Author: James M. G. Larkin

First Author: Nizar M. Tannir

Poster

2022 ASCO Genitourinary Cancers Symposium

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

Assessing physician prescribing behaviors in first-line (1L) advanced renal cell carcinoma (aRCC): A case-based study.

First Author: Ajeet Gajra